| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10753-007-9056-9 |
| P698 | PubMed publication ID | 18193345 |
| P50 | author | Barbara Rogala | Q86841382 |
| Alicja Kasperska-Zając | Q89308720 | ||
| Zenon Brzoza | Q96062855 | ||
| P2860 | cites work | Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase | Q24562119 |
| Enhancement of leukotriene B4 release in stimulated asthmatic neutrophils by platelet activating factor | Q28379398 | ||
| Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice | Q28609411 | ||
| Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma | Q33848692 | ||
| Inhibition of eosinophil activation in bronchoalveolar lavage fluid from atopic asthmatics by Y-24180, an antagonist to platelet-activating factor | Q33882008 | ||
| Platelet-activating factor causes ventilation-perfusion mismatch in humans | Q34119627 | ||
| Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma | Q34294834 | ||
| Anti-inflammatory properties of a platelet-activating factor acetylhydrolase | Q34307399 | ||
| Plasma platelet activating factor-acetylhydrolase (PAF-AH). | Q35053472 | ||
| Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children | Q35594599 | ||
| Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. | Q36562727 | ||
| Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms | Q37577289 | ||
| Bronchial hyper-reactivity: recent preclinical developments. | Q39700960 | ||
| Mediators of hypersensitivity and inflammatory cells in the pathogenesis of bronchial asthma | Q40210092 | ||
| Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response | Q40897920 | ||
| Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. | Q40920142 | ||
| Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man | Q41142725 | ||
| Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients | Q41211488 | ||
| Platelet activating factor: effects on bronchomotor tone and bronchial responsiveness in human beings. | Q41299868 | ||
| Effect of platelet activating factor (PAF) on the migration of human lymphocytes | Q41832882 | ||
| The effect of platelet-activating factor on the generation of superoxide anion in human eosinophils and neutrophils | Q41947992 | ||
| No increase in plasma histamine during PAF-induced airway obstruction in allergic asthmatics | Q42506856 | ||
| Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. | Q42553679 | ||
| Platelet-activating factor in bronchoalveolar lavage fluid from asthmatic subjects | Q44212769 | ||
| Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings | Q44619246 | ||
| The evidence of platelet activation in bronchial asthma | Q44665675 | ||
| Stimulation of degranulation from human eosinophils by platelet-activating factor | Q44876673 | ||
| Platelet activating factor does not cause a reproducible increase in bronchial responsiveness in normal man. | Q45003202 | ||
| Skin eosinophilia in atopic patients | Q46226400 | ||
| Mechanism of platelet activating factor-induced vascular leakage in the rat trachea | Q46228069 | ||
| Lack of systemic oxidative stress during PAF challenge in mild asthma | Q46432305 | ||
| Suppressive effects of Y-24180, a receptor antagonist to platelet activating factor (PAF), on antigen-induced asthmatic responses in guinea pigs | Q46870493 | ||
| Expression of platelet-activating factor receptor mRNA in human and guinea pig lung | Q46963411 | ||
| PAF responsiveness in Japanese subjects with plasma PAF acetylhydrolase deficiency | Q48000951 | ||
| Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans | Q48448770 | ||
| Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans | Q49121602 | ||
| Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. | Q50901799 | ||
| Increased levels of blood platelet-activating factor in bronchial asthmatic patients with active symptoms. | Q51597258 | ||
| Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. | Q52491574 | ||
| Discovery and preliminary pharmacology of Sch 37370, a dual antagonist of PAF and histamine | Q53852382 | ||
| Bronchoconstriction and eosinophil recruitment in guinea pig lungs after platelet activating factor administration. | Q53976935 | ||
| Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. | Q54135393 | ||
| Salbutamol inhibits pulmonary effects of platelet activating factor in man. | Q54171130 | ||
| Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. | Q54432169 | ||
| Bronchoconstriction induced by intratracheal administration of platelet-activating factor (PAF-acether) in baboons | Q54527263 | ||
| Induction of IL-4 by platelet-activating factor | Q60499029 | ||
| Platelet-activating factor enhances interleukin-6 production by alveolar macrophages | Q67506279 | ||
| Effect of SR 27417 on oedema formation induced in rabbit skin by platelet-activating factor or antigen | Q67554476 | ||
| The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils | Q67596956 | ||
| Basophil histamine release by platelet-activating factor in aspirin-sensitive subjects with asthma | Q67674678 | ||
| Platelet-activating factor does not induce bronchial hyperreactivity in nonasthmatic subjects | Q67990113 | ||
| Enhanced production of platelet activating factor by peripheral granulocytes from children with asthma | Q68030664 | ||
| Platelet activating factor (PAF) is a potent stimulator of porcine tracheal fluid secretion in vitro | Q68535454 | ||
| Histamine release from human leukocytes by platelet-activating factor | Q69021888 | ||
| Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils | Q69649642 | ||
| Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man | Q69883641 | ||
| The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction | Q70119869 | ||
| Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children | Q70128019 | ||
| Occupancy of platelet receptors for platelet-activating factor in asthmatic patients during an allergen-induced bronchoconstrictive reaction | Q70482614 | ||
| Inhibition of platelet-activating factor-induced bronchoconstriction by the leukotriene D4 receptor antagonist ICI 204,219 | Q70530056 | ||
| Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen | Q70530101 | ||
| Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy | Q70568778 | ||
| Release of PAF-acether from human blood monocytes | Q70575047 | ||
| PAF-acether-induced plasma exudation in rat skin is independent of platelets and neutrophils | Q70810376 | ||
| Platelet-activating factor: a possible mediator of the dual response to allergen? | Q71271374 | ||
| Acute bronchial obstruction following inhalation of PAF in asthmatic and normal subjects: comparison with methacholine | Q71605121 | ||
| Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine | Q72075181 | ||
| Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma | Q72204971 | ||
| Effect of cetirizine, a potent H1 antagonist, on platelet activating factor induced bronchoconstriction in asthma | Q72231521 | ||
| The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma | Q72398982 | ||
| Functional platelet-activating factor receptors are expressed by monocytes and granulocytes but not by resting or activated T and B lymphocytes from normal individuals or patients with asthma | Q72526941 | ||
| Allergen exposure in acute asthma causes the release of platelet-activating factor (PAF) as demonstrated by the desensitization of platelets to PAF | Q72626938 | ||
| Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation | Q72885839 | ||
| Platelet-activating factor-induced human eosinophil transendothelial migration: evidence for a dynamic role of the endothelium | Q72940249 | ||
| Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: a pilot study | Q73136760 | ||
| Anti-inflammatory actions of lipoxin A(4) stable analogs are demonstrable in human whole blood: modulation of leukocyte adhesion molecules and inhibition of neutrophil-endothelial interactions | Q73254109 | ||
| Recombinant human platelet-activating factor-acetylhydrolase inhibits airway inflammation and hyperreactivity in mouse asthma model | Q73520608 | ||
| Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses | Q73528566 | ||
| Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilation | Q73528570 | ||
| Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage | Q73528655 | ||
| PAF-induced eosinophil chemotaxis increases during an asthmatic attack and is inhibited by prednisolone in vivo and in vitro | Q73614770 | ||
| Comparison of platelet-activating factor receptor mRNA levels in peripheral blood eosinophils from normal subjects and atopic asthmatic patients | Q73863415 | ||
| Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses | Q74139228 | ||
| Plasma platelet-activating factor acetylhydrolase deficiency in Japanese patients with asthma | Q74529450 | ||
| The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma | Q74593222 | ||
| Inflammatory mediators of asthma: an update | Q77710217 | ||
| Evidence for an association between plasma platelet-activating factor acetylhydrolase deficiency and increased risk of childhood atopic asthma | Q77826813 | ||
| Platelet-activating factor increases the expression of metalloproteinase-9 in human bronchial epithelial cells | Q78048304 | ||
| P433 | issue | 2 | |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 112-120 | |
| P577 | publication date | 2008-01-12 | |
| P1433 | published in | Inflammation | Q2560341 |
| P1476 | title | Platelet activating factor as a mediator and therapeutic approach in bronchial asthma | |
| P478 | volume | 31 |
| Q34797862 | A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal Neovascularization and Subretinal Fibrosis |
| Q42362953 | A new player in interstitial cystitis/bladder pain syndrome: platelet-activating factor - PAF and its connection to smoking |
| Q34110525 | Contribution of classic and alternative effector pathways in peanut-induced anaphylactic responses |
| Q34172485 | Drug repositioning using in silico compound profiling |
| Q91807444 | Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives |
| Q34020321 | GM2 activator protein inhibits platelet activating factor signaling in rats |
| Q58801775 | Hydroxysafflor Yellow A Suppresses Platelet Activating Factor-Induced Activation of Human Small Airway Epithelial Cells |
| Q55446683 | Inflammation, not Cholesterol, Is a Cause of Chronic Disease. |
| Q28276574 | Lipid Mediators of Allergic Disease: Pathways, Treatments, and Emerging Therapeutic Targets |
| Q36100395 | Mast cell biology: introduction and overview |
| Q37727741 | Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis |
| Q37191286 | Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease |
| Q24629279 | Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor |
| Q58161307 | Progress in the Development of Platelet-Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases |
| Q36663974 | Risk of Migraine in Patients With Asthma: A Nationwide Cohort Study. |
| Q46758426 | Role of interleukin-18 in the pathophysiology of allergic diseases |
| Q36240870 | Sphingosine-1-phosphate and other lipid mediators generated by mast cells as critical players in allergy and mast cell function |
| Q27022598 | Stress triggers coronary mast cells leading to cardiac events |
| Q43689845 | The effect of rupatadine on lung histopathology in a murine model of chronic asthma. |
Search more.